PADMANEE SHARMA to B7-H1 Antigen
This is a "connection" page, showing publications PADMANEE SHARMA has written about B7-H1 Antigen.
Connection Strength
1.731
-
Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275. Clin Cancer Res. 2020 10 01; 26(19):5120-5128.
Score: 0.433
-
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555.
Score: 0.347
-
Immune checkpoint therapy-current perspectives and future directions. Cell. 2023 04 13; 186(8):1652-1669.
Score: 0.132
-
Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ? Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer. Clin Cancer Res. 2021 07 15; 27(14):3926-3935.
Score: 0.114
-
Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 2020 02; 20(2):75-76.
Score: 0.106
-
Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. Eur Urol. 2019 11; 76(5):599-603.
Score: 0.101
-
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. J Clin Oncol. 2019 07 01; 37(19):1608-1616.
Score: 0.101
-
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J Clin Invest. 2018 04 02; 128(4):1338-1354.
Score: 0.092
-
A potential biomarker for anti-PD-1 immunotherapy. Nat Med. 2018 02 07; 24(2):123-124.
Score: 0.092
-
Immune Checkpoint Therapy and the Search for Predictive Biomarkers. Cancer J. 2016 Mar-Apr; 22(2):68-72.
Score: 0.081
-
PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014 Apr; 2(4):361-70.
Score: 0.069
-
Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients. J Cutan Pathol. 2017 Dec; 44(12):1080-1086.
Score: 0.023
-
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
Score: 0.021
-
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2015 Sep; 3(9):1017-29.
Score: 0.019